SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: Roots Analysis | PRODUCT CODE: 2112606

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 2112606

Therapeutic Vaccines Market by Type of Vaccine, Method of Vaccine Composition, Type of Therapy, Therapeutic Area, Route of Administration, Key Geographical Regions - Trends and Forecast Till 2035

PUBLISHED:
PAGES: 306 Pages
DELIVERY TIME: 7-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4799
PDF & Excel & Summary Pack (Business Unit License)
USD 7999
PDF & Excel & Summary Pack (Enterprise License)
USD 17999

Add to Cart

Description

Table of Contents

List of Tables

THERAPEUTIC VACCINES MARKET: OVERVIEW

As per Roots Analysis, the global therapeutic vaccines market is estimated to grow from USD 11.0 billion in the current year to USD 86.8 billion by 2035, reflecting a compound annual growth rate (CAGR) of approximately 25.8% during the forecast period.

Therapeutic Vaccines Market - IMG1

Therapeutic Vaccines Market: Growth and Trends

Unlike prophylactic vaccines, which are administered to healthy individuals to prevent disease, therapeutic vaccines are designed to be given after a disease has already taken hold, with the goal of training the immune system to recognize and act against it. Their efficacy generally trails that of prophylactic formulations, but they offer a safety, specificity, and durability profile that has made them an attractive modality for oncology and chronic infectious disease, and they are also being explored for individuals whose own antibody response is insufficient to control an existing infection.

For much of the past two decades, the therapeutic melanoma vaccine field has been driven by considerable clinical interest, however, despite significant advances in melanoma immunotherapy, no therapeutic melanoma vaccine has yet received full USFDA approval. That gap between promise and product is now narrowing. More than 400 cancer vaccine clinical trials are currently active worldwide, and over 300 cancer vaccine candidates are currently being developed for a broad range of oncological indications, supported by steady advances in adjuvant science and formulation stability.

A defining shift in the space is the move toward next generation neoantigen mRNA vaccines. Built on genomic sequencing, bioinformatics, and personalized-medicine platforms, these candidates are designed against a patient's own tumor-specific neoantigens rather than shared antigens, improving precision and immune activation relative to earlier cancer vaccine generations. Recently, Moderna and Merck jointly reported that their investigational personalized cancer vaccine, used alongside Keytruda, sustained a meaningful reduction in recurrence or death risk in melanoma patients. These clinical results are reinforcing confidence in this approach and drawing continued capital toward the neoantigen and mRNA vaccine segment.

Growth Drivers: Factors Fueling Market Expansion

The rising global burden of cancer, together with the persistence of chronic infectious diseases such as HIV, HBV, and HCV, is a central driver of this market. These conditions typically involve prolonged disease courses, high relapse rates, and significant treatment costs, creating a clear clinical case for durable immune-based therapies. As screening and diagnostic capabilities improve across geographies, more patients are being identified early enough for therapeutic vaccination to be incorporated into their treatment plans, widening the addressable patient pool.

Parallel advances in immuno-oncology and vaccine engineering, including DNA and mRNA platforms, improved adjuvants, next-generation vectors, and neoantigen-based design, are enabling vaccines that generate stronger and more targeted T-cell responses. These platforms are also easier to customize for individual tumors or patients, aligning naturally with the broader industry shift toward precision medicine and reinforcing sustained R&D investment in the category.

Market Challenges: Critical Barriers Hindering Progress

Despite this momentum, therapeutic vaccines continue to face a translational gap between preclinical promise and real-world patient outcomes. Human immune responses, particularly in complex diseases such as cancer, are harder to control than in laboratory or animal models, and tumor and patient heterogeneity mean that a vaccine effective in one individual may perform poorly in another. This variability makes it difficult to demonstrate consistent, statistically robust benefit in clinical trials, and correspondingly difficult to displace established standard-of-care therapies.

Development itself is technically demanding. Sponsors must select the right antigens, delivery systems, adjuvants, and dosing regimens while safeguarding safety and efficacy, a process that carries a high rate of candidate attrition. Trial design is further complicated by diverse tumor types and disease stages across enrolled repeated late-stage setbacks have periodically dampened investor sentiment, slowing pipeline advancement for smaller developers in particular.

Therapeutic Vaccines Market: Key Insights

The report delves into the current state of the therapeutic vaccines market and identifies potential growth opportunities within the industry. Some key findings include:

  • Platform Flexibility Driving mRNA Expansion Across Oncology and Rare Diseases: Driven by the platform's inherent flexibility, high immunogenicity, and the pressing need for targeted treatment options, an expanding base of biopharmaceutical innovators and large pharmaceutical companies is prioritizing mRNA-based drug development across complex oncology and rare disease indications.
  • Pipeline Concentration Among Industry Trailblazers: Over 300 therapeutic vaccine candidates are under active investigation across various stages of clinical development. Notably, approximately 70% of active pipeline activity remains concentrated among market leaders Moderna and BioNTech, underscoring an intense consolidation of developer expertise.
  • Accelerating Strategic Alliances Between Platform Owners and Indication Specialists: Deal flow targeting novel disease mechanisms continues to gather momentum. For instance, Moderna partnered with Recordati to advance mRNA-3927, its investigational mRNA candidate for propionic acidemia, through development and toward eventual commercialization.
  • Robust Early-Stage Venture Capital and Seed Funding Inflows: Private equity and venture investments into mRNA-focused platforms have risen steadily, providing companies with crucial runway to advance candidates toward pivotal clinical evaluations. Early-stage funding reflects this trend: Reprogram Biosciences raised USD 6 million in seed funding in May to advance its proprietary mRNA-based in situ cell reprogramming approach designed to transform tumor beds into active antigen-presenting sites. Additionally, ErVimmune closed a €17 million Series A to push its therapeutic cancer vaccine ErVac01 into human trials.
  • Clinical Maturity and Late-Stage Advancement: More than 10% of the global therapeutic vaccines pipeline has reached Phase III, reflecting an unusually high late-stage proportion for an emerging biological modality. While this signals growing regulatory acceptance and clinical maturity, overall pipeline leadership remains heavily anchored by first-mover pioneers.
  • Shift Toward M&A and Licensing Over In-House Platform Development: Rather than constructing internal mRNA capabilities from scratch, large pharmaceutical incumbents are actively acquiring or entering deep collaboration agreements with specialized RNA developers. Pfizer leads this trend through multi-target platform alliances, followed by Sanofi (which expanded its core RNA infrastructure via the acquisition of Translate Bio), and Bayer, which continues to enter targeted clinical collaborations.

Therapeutic Vaccines Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Vaccine

  • Peptide Vaccines
  • Antigen Vaccines
  • DNA Vaccines
  • Dendritic Vaccines

By Method of Vaccine Composition

  • Autologous Vaccines
  • Allogeneic Vaccines

By Type of Therapy

  • Monotherapies
  • Combination Therapies

By Therapeutic Area

  • Oncological Disorders
  • Infectious Diseases
  • Autoimmune Disorders
  • Others

By Route of Administration

  • Intradermal Route
  • Intramuscular Route
  • Subcutaneous Route
  • Intranasal Route
  • Oral Route
  • Others

By Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Therapeutic Vaccines Market: Key Segments

Peptide Vaccines Lead the Market and DNA Vaccines Will Register Higher CAGR

Based on our market assessment, the peptide vaccines segment is expected to account for the largest share of the therapeutic vaccines market. This highest share is due to its high specificity, safety profile, and broad applicability across cancer immunotherapy and infectious disease treatment. These vaccines rely on selected antigenic peptides to stimulate targeted immune responses against disease-associated markers. Owing to their target specificity, these vaccines limit off-target effects and improve treatment outcomes. Further, their relatively simple design and manufacturing scalability have supported wide clinical adoption.

On the other hand, the DNA vaccines segment is projected to grow at a higher CAGR during the forecast period. This potential growth is supported by advances in genetic engineering and rising demand for next-generation vaccine platforms. DNA vaccines offer rapid design cycles, manufacturing flexibility, and the ability to trigger both humoral and cellular immunity, and growing investment in genomic medicine and precision immunotherapy is expected to accelerate their uptake.

Oncological Disorders Dominate the Market

Oncological disorders account for the largest share of the therapeutic vaccines market. This highest share reflects the global cancer burden and the growing role of therapeutic vaccination as an immunotherapy approach that stimulates the immune system to target tumor-specific antigens. Sustained investment in cancer research, a deepening pipeline of vaccine candidates, and closer integration with other immuno-oncology modalities continue to accelerate clinical development and eventual commercialization in this segment.

The infectious diseases segment is expected to grow fastest CAGR during the forecast period. This lucrative growth is driven by growing interest in therapeutic vaccines for chronic and difficult-to-treat viral and bacterial infections. Advances in DNA, RNA, and vector-based platforms are enabling novel approaches that strengthen immune response and reduce reliance on long-term antimicrobial therapy.

North America Maintains Market Leadership

According to our market projections, North America is expected to hold the majority share of the market in the current year. This highest share is supported by the advanced healthcare infrastructure, a strong biotechnology and pharmaceutical base, and substantial investment in immunotherapy R&D. Further, the region's mature clinical trial ecosystem, favorable regulatory pathways, and high prevalence of cancer and other chronic conditions continue to reinforce its lead position.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period. This lucrative growth is driven by rising healthcare expenditure, expanding biopharmaceutical research capacity, and a growing burden of cancer and infectious disease across China, India, Japan, and South Korea. Increasing government support for biotechnology innovation and improving clinical infrastructure are creating favorable conditions for accelerated regional expansion.

Example Players in Therapeutic Vaccines Market

  • BioNTech
  • GlobeImmune
  • Immatics
  • Immunitor
  • Inovio Pharmaceuticals
  • Moderna

Expert Interview and Industry Insights

The opinions and insights presented in this study were shaped by discussions held with multiple stakeholders across the therapeutic vaccines value chain. The research report features detailed transcripts of interviews conducted with the following industry stakeholders:

  • Chief Executive Officer and Chief Scientific Officer, Mid-sized Company, Italy
  • Science Director Advanced Modalities, Senior Research Leader, and Director of Scientific Advisory Services, Very Large Company, US
  • Director of Head and Neck Cancer Research, Very Large Company, US
  • Associate Professor of Surgery, Integrative Immunology, and Pathology, Very Large Institute, US
  • Physician Scientists, Very Large Institute, US
  • Pediatric Oncologist, Very Large Institute, US
  • Associate Director for Translational Research, Very Large Institute, US
  • Research Group Leader, Mid-sized Institute, Germany
  • Senior Public Health Researcher, Mid-sized Institute, India

THERAPEUTIC VACCINES MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: In-depth analysis of the therapeutic vaccines market across type of vaccine, method of vaccine composition, type of therapy, therapeutic area, route of administration, and geographical regions.
  • Market Landscape: A detailed pipeline assessment by phase of development, vaccine type, therapy type, therapeutic area, route of administration, and dosage, together with an analysis of vaccine developers by year of establishment, company size, and location of headquarters.
  • Company Profiles: In-depth profiles of prominent players engaged in developing therapeutic vaccines, covering year of establishment, headquarters, company size, financial information, portfolio, and recent developments.
  • Start-Up Health Indexing: Benchmarking of emerging vaccine developers by supplier strength, pipeline strength, pipeline maturity, financial investment, and partnership activity.
  • Clinical Trial Analysis: An analysis of registered clinical trials by registration year, phase, recruitment status, study design, focus area, therapeutic area, sponsor type, and geography.
  • Academic Grants Analysis: Assessment of research grants by year of award, amount awarded, administering institute, support period, and recipient organization.
  • Partnerships and Collaborations: A review of deal activity by year, type of partnership, type of partner, focus area, therapeutic area, and geographical distribution.
  • Market Forecast and Opportunity Analysis: Ten-year revenue forecasts for the global market and its sub-segments, together with country-level projections across twelve key markets.
  • Case Study, Preventive Vaccines Market: A comparative view of the marketed and clinical-stage preventive vaccines landscape, positioned as an adjacent-market benchmark for the therapeutic vaccines.
  • Case Study, Vaccine Contract Manufacturing Market: An overview of the vaccine CMO landscape by scale of operation, service offering, and expression system, relevant to distributors assessing supply-chain partners.

Key Questions Answered in this Report

  • Which companies are leading the therapeutic vaccines market?
  • Which region dominates the therapeutic vaccines market?
  • What are the key trends observed in the therapeutic vaccines market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by therapeutic vaccine developers?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
  • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

  • Complementary PPT Data Packs
  • Complementary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older
Show more
Product Code: RA100349

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Introduction to Therapeutic Vaccines
    • 6.2.1. Classification of Vaccines by Method of Composition
      • 6.2.1.1. Autologous Vaccines
      • 6.2.1.2. Allogeneic Vaccines
  • 6.3. Classification of Vaccines by Mechanism of Action
    • 6.3.1. Antigen Vaccines
    • 6.3.2. Dendritic Vaccines
    • 6.3.3. DNA Vaccines
    • 6.3.4. Peptide Vaccines
  • 6.4. Key Target Indications
    • 6.4.1. Cancer
    • 6.4.2. HIV Infection
    • 6.4.3. HPV Infection
    • 6.4.4. Herpes
  • 6.5. Clinical Development and Approval of Vaccines
  • 6.6. Concluding Remarks

7. MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Therapeutic Vaccines: Pipeline Analysis
    • 7.2.1. Analysis by Phase of Development
    • 7.2.2. Analysis by Type of Vaccine
    • 7.2.3. Analysis by Type of Vaccine (by Method of Composition)
    • 7.2.4. Analysis by Type of Therapy
    • 7.2.5. Analysis by Therapeutic Area
    • 7.2.6. Analysis by Route of Administration
    • 7.2.7. Analysis by Dosage
  • 7.3. Therapeutic Vaccines: Analysis by Vaccine Developers
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
    • 7.3.4. Leading Developers
    • 7.3.5. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. BioNTech
    • 8.2.1. Company Overview
    • 8.2.2. Financial Information
    • 8.2.3. Therapeutic Vaccines Portfolio
    • 8.2.4. Recent Developments and Future Outlook

Similar details are presented for other companies mentioned below (based on information in the public domain)

  • 8.3. Brii Biosciences
  • 8.4. GlobeImmune
  • 8.5. Immatics
  • 8.6. Immune Response Biopharma
  • 8.7. Immunitor
  • 8.8. Inovio Pharmaceuticals
  • 8.9. Moderna

9. START-UP HEALTH INDEXING

  • 9.1. Chapter Overview
  • 9.2. Start-ups in Therapeutic Vaccines Market
    • 9.2.1. Analysis by Location of Headquarters
  • 9.3. Benchmarking of Start-ups
    • 9.3.1. Analysis by Supplier Strength
    • 9.3.2. Analysis by Pipeline Strength
    • 9.3.3. Analysis by Pipeline Maturity
    • 9.3.4. Analysis by Financial Investment
    • 9.3.5. Analysis by Partnership Activity
    • 9.3.6. Start-ups Health Indexing: Roots Analysis Perspective

10. CLINICAL TRIAL ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Therapeutic Vaccines: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Registration Year
    • 10.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
    • 10.3.3. Analysis by Trial Phase
    • 10.3.4. Analysis by Trial Recruitment Status
    • 10.3.5. Analysis by Study Design
    • 10.3.6. Analysis by Trial Focus Area
    • 10.3.7. Analysis by Therapeutic Area
    • 10.3.8. Analysis by Type of Sponsor / Collaborator
    • 10.3.9. Most Active Players: Analysis by Number of Registered Trials
    • 10.3.10. Geographical Analysis by Number of Registered Trials
    • 10.3.11. Geographical Analysis by Enrolled Patient Population

11. ACADEMIC GRANTS ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Therapeutic Vaccines: Academic Grant Analysis
    • 11.3.1. Analysis by Year of Grant Award
    • 11.3.2. Analysis by Amount Awarded
    • 11.3.3. Analysis by Administering Institute Center
    • 11.3.4. Analysis by Support Period
    • 11.3.5. Analysis by Administering Institute Center and Support Period
    • 11.3.6. Analysis by Type of Grant Application
    • 11.3.7. Analysis by Purpose of Grant Award
    • 11.3.8. Analysis by Activity Code
    • 11.3.9. Analysis by Study Section Involved
    • 11.3.10. Analysis by Type of Recipient Organization
    • 11.3.11. Word Cloud Analysis: Emerging Focus Areas
    • 11.3.12. Geographical Distribution of Recipient Organizations
    • 11.3.13. Popular NIH Departments: Analysis by Number of Grants
    • 11.3.14. Prominent Program Officers: Analysis by Number of Grants
    • 11.3.15. Popular Recipient Organizations: Analysis by Number of Grants

12. PARTNERSHIPS AND COLLABORATIONS

  • 12.1. Chapter Overview
  • 12.2. Partnership Models
  • 12.3. Therapeutic Vaccines: Partnerships and Collaborations
    • 12.3.1. Analysis by Year of Partnership
    • 12.3.2. Analysis by Type of Partnership
    • 12.3.3. Analysis by Year of Partnership and Type of Partner
    • 12.3.4. Analysis by Type of Partnership and Type of Partner
    • 12.3.5. Analysis by Focus Area
    • 12.3.6. Analysis by Therapeutic Area
    • 12.3.7. Most Active Players: Analysis by Number of Partnerships
    • 12.3.8. Regional Analysis
      • 12.3.8.1. Intercontinental and Intracontinental Agreements

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Global Therapeutic Vaccines Market, till 2035
  • 13.4. Global Therapeutic Vaccines Market, till 2035: Distribution by Type of Vaccine
  • 13.5. Global Therapeutic Vaccines Market, till 2035: Distribution by Method of Vaccine Composition
  • 13.6. Global Therapeutic Vaccines Market, till 2035: Distribution by Type of Therapy
  • 13.7. Global Therapeutic Vaccines Market, till 2035: Distribution by Therapeutic Area
  • 13.8. Global Therapeutic Vaccines Market, till 2035: Distribution by Route of Administration
  • 13.9. Global Therapeutic Vaccines Market, till 2035: Geographical Distribution
    • 13.9.1. Therapeutic Vaccines Market in US, till 2035
    • 13.9.2. Therapeutic Vaccines Market in Canada, till 2035
    • 13.9.3. Therapeutic Vaccines Market in UK, till 2035
    • 13.9.4. Therapeutic Vaccines Market in Germany, till 2035
    • 13.9.5. Therapeutic Vaccines Market in France, till 2035
    • 13.9.6. Therapeutic Vaccines Market in Italy, till 2035
    • 13.9.7. Therapeutic Vaccines Market in Spain, till 2035
    • 13.9.8. Therapeutic Vaccines Market in Australia, till 2035
    • 13.9.9. Therapeutic Vaccines Market in Japan, till 2035
    • 13.9.10. Therapeutic Vaccines Market in Korea, till 2035
    • 13.9.11. Therapeutic Vaccines Market in Brazil, till 2035
    • 13.9.12. Therapeutic Vaccines Market in Israel, till 2035
  • 13.10. Global Therapeutic Vaccines Market, till 2035: Sales Forecast

14. CASE STUDY: GLOBAL PREVENTIVE VACCINES

  • 14.1. Chapter Overview
  • 14.2. Preventive Vaccines: Overall Market Landscape
    • 14.2.1. Marketed Vaccines Landscape
    • 14.2.2. Clinical-Stage Vaccines Landscape
    • 14.2.3. Analysis by Phase of Development
    • 14.2.4. Analysis by Route of Administration
    • 14.2.5. Analysis by Type of Vaccine API
    • 14.2.6. Analysis by Dosage Form
    • 14.2.7. Analysis by Therapeutic Area
    • 14.2.8. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
    • 14.2.9. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development

15. CASE STUDY: VACCINE CONTRACT MANUFACTURING MARKET

  • 15.1. Chapter Overview
  • 15.2. Vaccine Contract Manufacturers: Overall Market Landscape
    • 15.2.1. Analysis by Year of Establishment
    • 15.2.2. Analysis by Company Size and Geographical Location
    • 15.2.3. Analysis by Geography
    • 15.2.4. Analysis by Type of Service(s) Offered
    • 15.2.5. Analysis by Scale of Operation
    • 15.2.6. Analysis by Type of Expression System(s) Used
    • 15.2.7. Analysis by Type of Vaccines Manufactured

16. CONCLUDING REMARKS

17. EXECUTIVE INSIGHTS

18. APPENDIX I: TABULATED DATA

19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Show more
Product Code: RA100349

List of Tables

  • Table 6.1 Vaccines for Cancer Treatment
  • Table 6.2 Vaccines for HIV Treatment
  • Table 6.3 Vaccines for HPV Treatment
  • Table 6.4 Vaccines for Herpes Treatment
  • Table 7.1 List of Therapeutic Vaccines
  • Table 8.1 Global Therapeutic Vaccines: List of Companies Profiled
  • Table 8.2 BioNTech: Company Snapshot
  • Table 8.3 Vaccine Profile: BNT-111
  • Table 8.4 Vaccine Profile: BNT-112
  • Table 8.5 Vaccine Profile: BNT-113
  • Table 8.6 Vaccine Profile: BNT-115
  • Table 8.7 Vaccine Profile: BNT-116
  • Table 8.8 Vaccine Profile: BNT-122
  • Table 8.9 Vaccine Profile: W_pro1
  • Table 8.10 Vaccine Profile: HPV Vaccine
  • Table 8.11 Vaccine Profile: IVAC MUTANOME
  • Table 8.12 Vaccine Profile: RBL001/RBL002
  • Table 8.13 Vaccine Profile: NEO-PV-01
  • Table 8.14 BioNTech: Recent Developments and Future Outlook
  • Table 8.15 Brii Biosciences: Company Snapshot
  • Table 8.16 Vaccine Profile: Bri-179
  • Table 8.17 Vaccine Profile: Bri-835
  • Table 8.18 Vaccine Profile: Bri-778
  • Table 8.19 Vaccine Profile: Bri-732
  • Table 8.20 Vaccine Profile: Bri-296
  • Table 8.21 Brii Biosciences: Recent Developments and Future Outlook
  • Table 8.22 GlobeImmune: Company Snapshot
  • Table 8.23 Vaccine Profile: GI-6301
  • Table 8.24 Vaccine Profile: GI-6207
  • Table 8.25 Vaccine Profile: GI-4000
  • Table 8.26 Vaccine Profile: GS-4774
  • Table 8.27 Vaccine Profile: GI-5005
  • Table 8.28 GlobeImmune: Recent Developments and Future Outlook
  • Table 8.29 Immatics: Company Snapshot
  • Table 8.30 Vaccine Profile: APVAC
  • Table 8.31 Vaccine Profile: IMA901
  • Table 8.32 Vaccine Profile: IMA910
  • Table 8.33 Vaccine Profile: IMA950
  • Table 8.34 Vaccine Profile: IMA970A
  • Table 8.35 Immatics: Recent Developments and Future Outlook
  • Table 8.36 Immune Response Biopharma: Company Snapshot
  • Table 8.37 Vaccine Profile: IR103
  • Table 8.38 Vaccine Profile: REMUNE
  • Table 8.39 Vaccine Profile: NeuroVax
  • Table 8.40 Vaccine Profile: RAVAX
  • Table 8.41 Vaccine Profile: Zorcell
  • Table 8.42 Immune Response Biopharma: Recent Developments and Future Outlook
  • Table 8.43 Immunitor: Company Snapshot
  • Table 8.44 Vaccine Profile: Atherosclerosis Vaccine
  • Table 8.45 Vaccine Profile: V3-MOMMO
  • Table 8.46 Vaccine Profile: Hepcortespenlisimut-L
  • Table 8.47 Vaccine Profile: V-Boost
  • Table 8.48 Vaccine Profile: V3-OVA
  • Table 8.49 Vaccine Profile: V3-Myoma
  • Table 8.50 Vaccine Profile: V3-Cervix
  • Table 8.51 Vaccine Profile: V7
  • Table 8.52 Vaccine Profile: V3-X
  • Table 8.53 Vaccine Profile: V3-P
  • Table 8.54 Vaccine Profile: V-Endo
  • Table 8.55 Vaccine Profile: V8
  • Table 8.56 Vaccine Profile: V-SARS
  • Table 8.57 Immunitor: Recent Developments and Future Outlook
  • Table 8.58 Innovio Pharmaceuticals: Company Snapshot
  • Table 8.59 Vaccine Profile: VGX-3100
  • Table 8.60 Vaccine Profile: INO-3107
  • Table 8.61 Vaccine Profile: INO-5401
  • Table 8.62 Vaccine Profile: INO-5151
  • Table 8.63 Vaccine Profile: INO-3112
  • Table 8.64 Vaccine Profile: INO-5150
  • Table 8.65 Vaccine Profile: INO-3106
  • Table 8.66 Vaccine Profile: INO-1800
  • Table 8.67 Innovio Pharmaceuticals: Recent Developments and Future Outlook
  • Table 8.68 Moderna: Company Snapshot
  • Table 8.69 Vaccine Profile: mRNA-4157
  • Table 8.70 Vaccine Profile: mRNA-3927
  • Table 8.71 Vaccine Profile: mRNA-3705
  • Table 8.72 Vaccine Profile: mRNA-3745
  • Table 8.73 Vaccine Profile: mRNA-5671
  • Table 8.74 Vaccine Profile: mRNA-2752
  • Table 8.75 Moderna: Recent Developments and Future Outlook
  • Table 12.1 Global Therapeutic Vaccines: List of Partnerships and Collaborations, Since 2021
  • Table 14.1 Therapeutic Vaccines: Distribution by Phase of Development
  • Table 14.2 Therapeutic Vaccines: Distribution by Type of Vaccine
  • Table 14.3 Therapeutic Vaccines: Distribution by Type of Vaccine (by Method of Composition)
  • Table 14.4 Therapeutic Vaccines: Distribution by Type of Therapy
  • Table 14.5 Therapeutic Vaccines: Distribution by Therapeutic Area
  • Table 14.6 Therapeutic Vaccines: Distribution by Route of Administration
  • Table 14.7 Therapeutic Vaccines: Distribution by Dosage
  • Table 14.8 Therapeutic Vaccines Developers: Distribution by Type of Developers
  • Table 14.9 Therapeutic Vaccines Developers: Distribution by Year of Establishment
  • Table 14.10 Therapeutic Vaccines Developers: Distribution by Company Size
  • Table 14.11 Therapeutic Vaccines Developers: Distribution by Location of Headquarters
  • Table 14.12 Leading Developers
  • Table 14.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
  • Table 14.14 BioNTech: Annual Revenues, Since 2021 (USD Million)
  • Table 14.15 Brii Biosciences: Annual Revenues, Since 2021 (USD Million)
  • Table 14.16 GlobeImmune: Annual Revenues, Since 2021 (USD Million)
  • Table 14.17 Immatics: Annual Revenues, Since 2021 (USD Million)
  • Table 14.18 Immune Response Biopharma: Annual Revenues, Since 2021 (USD Million)
  • Table 14.19 Inovio Pharmaceuticals: Annual Revenues, Since 2021 (USD Million)
  • Table 14.20 Moderna: Annual Revenues, Since 2021 (USD Million)
  • Table 14.21 Clinical Trial Analysis: Scope and Methodology
  • Table 14.22 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
  • Table 14.23 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2022
  • Table 14.24 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 14.25 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Table 14.26 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Table 14.27 Clinical Trial Analysis: Distribution by Study Design
  • Table 14.28 Clinical Trial Analysis: Distribution by Trial Focus Area
  • Table 14.29 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 14.30 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 14.31 Most Active Players: Distribution by Number of Registered Trials
  • Table 14.32 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Table 14.33 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Table 14.34 Grant Analysis: Cumulative Year-wise Trend, 2016-2022
  • Table 14.35 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million) 2016-2022
  • Table 14.36 Grant Analysis: Distribution by Administering Institute Center
  • Table 14.37 Grant Analysis: Distribution by Support Period
  • Table 14.38 Grant Analysis: Distribution by Administering Institute Center and Support Period
  • Table 14.39 Grant Analysis: Distribution by Type of Grant Application
  • Table 14.40 Grant Analysis: Distribution by Purpose of Grant Award
  • Table 14.41 Grant Analysis: Distribution by Activity Code
  • Table 14.42 Grant Analysis: Distribution by Study Section Involved
  • Table 14.43 Grant Analysis: Distribution by Type of Recipient Organization
  • Table 14.44 Grant Analysis: Geographical Distribution of Recipient Organizations
  • Table 14.45 Popular NIH Departments: Distribution by Number of Grants
  • Table 14.46 Prominent Program Officers: Distribution by Number of Grants
  • Table 14.47 Popular Recipient Organizations: Distribution by Number of Grants
  • Table 14.48 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
  • Table 14.49 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 14.50 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Table 14.51 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Table 14.52 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 14.53 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 14.54 Most Active Players: Distribution by Number of Partnerships
  • Table 14.55 Partnerships and Collaborations: Regional Distribution
  • Table 14.56 Startup-Health Indexing: Distribution by Location of Headquarters
  • Table 14.57 Startup-Health Indexing: Distribution by Supplier Strength
  • Table 14.58 Startup-Health Indexing: Distribution by Pipeline Strength
  • Table 14.59 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Table 14.60 Startup-Health Indexing: Distribution by Financial Investment
  • Table 14.61 Startup-Health Indexing: Distribution by Partnership Activity
  • Table 14.62 Startup-Health Indexing: Roots Analysis Perspective
  • Table 14.63 Global Therapeutic Vaccines Market, 2022-2035 (USD Million)
  • Table 14.64 Global Therapeutic Vaccines Market: Distribution by Type of Vaccine, till 2035
  • Table 14.65 Global Therapeutic Vaccines Market: Distribution by Method of Vaccine Composition, till 2035
  • Table 14.66 Global Therapeutic Vaccines Market: Distribution by Type of Therapy, till 2035
  • Table 14.67 Global Therapeutic Vaccines Market: Distribution by Therapeutic Area, till 2035
  • Table 14.68 Global Therapeutic Vaccines Market: Distribution by Route of Administration, till 2035
  • Table 14.69 Therapeutic Vaccines Market in US, till 2035
  • Table 14.70 Therapeutic Vaccines Market in Canada, till 2035
  • Table 14.71 Therapeutic Vaccines Market in UK, till 2035
  • Table 14.72 Therapeutic Vaccines Market in Germany, till 2035
  • Table 14.73 Therapeutic Vaccines Market in France, till 2035
  • Table 14.74 Therapeutic Vaccines Market in Italy, till 2035
  • Table 14.75 Therapeutic Vaccines Market in Spain, till 2035
  • Table 14.76 Therapeutic Vaccines Market in Australia, till 2035
  • Table 14.77 Therapeutic Vaccines Market in Japan, till 2035
  • Table 14.78 Therapeutic Vaccines Market in Korea, till 2035
  • Table 14.79 Therapeutic Vaccines Market in Brazil, till 2035
  • Table 14.80 Therapeutic Vaccines Market in Israel, till 2035

List of Figures

  • Figure 6.1 Difference between Preventive Vaccines and Therapeutic Vaccines
  • Figure 6.2 Different Routes of Vaccine Administration
  • Figure 7.1 Therapeutic Vaccines: Distribution by Phase of Development
  • Figure 7.2 Therapeutic Vaccines: Distribution by Type of Vaccine
  • Figure 7.3 Therapeutic Vaccines: Distribution by Type of Vaccine (by Method of Composition)
  • Figure 7.4 Therapeutic Vaccines: Distribution by Type of Therapy
  • Figure 7.5 Therapeutic Vaccines: Distribution by Therapeutic Area
  • Figure 7.6 Therapeutic Vaccines: Distribution by Route of Administration
  • Figure 7.7 Therapeutic Vaccines: Distribution by Dosage
  • Figure 7.8 Therapeutic Vaccines Developers: Distribution by Type of Developers
  • Figure 7.9 Therapeutic Vaccines Developers: Distribution by Year of Establishment
  • Figure 7.10 Therapeutic Vaccines Developers: Distribution by Company Size
  • Figure 7.11 Therapeutic Vaccines Developers: Distribution by Location of Headquarters
  • Figure 7.12 Leading Developers
  • Figure 7.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
  • Figure 8.1 BioNTech: Annual Revenues, Since 2021 (USD Million)
  • Figure 8.2 Brii Biosciences: Annual Revenues, Since 2021 (USD Million)
  • Figure 8.3 GlobeImmune: Annual Revenues, Since 2021 (USD Million)
  • Figure 8.4 Immatics: Annual Revenues, Since 2021 (USD Million)
  • Figure 8.5 Immune Response Biopharma: Annual Revenues, Since 2021 (USD Million)
  • Figure 8.6 Inovio Pharmaceuticals: Annual Revenues, Since 2021 (USD Million)
  • Figure 8.7 Moderna: Annual Revenues, Since 2021 (USD Million)
  • Figure 9.1 Startup-Health Indexing: Distribution by Location of Headquarters
  • Figure 9.2 Startup-Health Indexing: Distribution by Supplier Strength
  • Figure 9.3 Startup-Health Indexing: Distribution by Pipeline Strength
  • Figure 9.4 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Figure 9.5 Startup-Health Indexing: Distribution by Financial Investment
  • Figure 9.6 Startup-Health Indexing: Distribution by Partnership Activity
  • Figure 9.7 Startup-Health Indexing: Roots Analysis Perspective
  • Figure 9.8 Spider Web Analysis: Leading Companies
  • Figure 10.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 10.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2021
  • Figure 10.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2021
  • Figure 10.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 10.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Figure 10.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Figure 10.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 10.8 Clinical Trial Analysis: Distribution by Trial Focus Area
  • Figure 10.9 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 10.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 10.11 Most Active Players: Distribution by Number of Registered Trials
  • Figure 10.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Figure 10.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Figure 11.1 Grant Analysis: Cumulative Year-wise Trend, Since 2021
  • Figure 11.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million) Since 2021
  • Figure 11.3 Grant Analysis: Distribution by Administering Institute Center
  • Figure 11.4 Grant Analysis: Distribution by Support Period
  • Figure 11.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
  • Figure 11.6 Grant Analysis: Distribution by Type of Grant Application
  • Figure 11.7 Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 11.8 Grant Analysis: Distribution by Activity Code
  • Figure 11.9 Grant Analysis: Distribution by Study Section Involved
  • Figure 11.10 Grant Analysis: Distribution by Type of Recipient Organization
  • Figure 11.11 Word Cloud Analysis: Emerging Focus Areas
  • Figure 11.12 Grant Analysis: Geographical Distribution of Recipient Organizations
  • Figure 11.13 Popular NIH Departments: Distribution by Number of Grants
  • Figure 11.14 Prominent Program Officers: Distribution by Number of Grants
  • Figure 11.15 Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
  • Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 12.3 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Figure 12.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 12.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 12.6 Partnerships and Collaborations: Distribution by Focus Areas
  • Figure 12.7 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 12.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 12.9 Partnerships and Collaborations: Regional Distribution
  • Figure 12.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 13.1 Global Therapeutic Vaccines Market, till 2035 (USD Million)
  • Figure 13.2 Global Therapeutic Vaccines Market: Distribution by Type of Vaccine, till 2035
  • Figure 13.3 Global Therapeutic Vaccines Market: Distribution by Method of Vaccine Composition, till 2035
  • Figure 13.4 Global Therapeutic Vaccines Market: Distribution by Type of Therapy, till 2035
  • Figure 13.5 Global Therapeutic Vaccines Market: Distribution by Therapeutic Area, till 2035
  • Figure 13.6 Global Therapeutic Vaccines Market: Distribution by Route of Administration, till 2035
  • Figure 13.7 Therapeutic Vaccines Market in US, till 2035
  • Figure 13.8 Therapeutic Vaccines Market in Canada, till 2035
  • Figure 13.9 Therapeutic Vaccines Market in UK, till 2035
  • Figure 13.10 Therapeutic Vaccines Market in Germany, till 2035
  • Figure 13.11 Therapeutic Vaccines Market in France, till 2035
  • Figure 13.12 Therapeutic Vaccines Market in Italy, till 2035
  • Figure 13.13 Therapeutic Vaccines Market in Spain, till 2035
  • Figure 13.14 Therapeutic Vaccines Market in Australia, till 2035
  • Figure 13.15 Therapeutic Vaccines Market in Japan, till 2035
  • Figure 13.16 Therapeutic Vaccines Market in Korea, till 2035
  • Figure 13.17 Therapeutic Vaccines Market in Brazil, till 2035
  • Figure 13.18 Therapeutic Vaccines Market in Israel, till 2035
  • Figure 14.1 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
  • Figure 14.2 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
  • Figure 14.3 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
  • Figure 14.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
  • Figure 14.5 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
  • Figure 14.6 Clinical-Stage Preventive Vaccines: Distribution by Therapeutic Area
  • Figure 14.7 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
  • Figure 14.8 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
  • Figure 15.1 Vaccine CMOs: Distribution by Year of Establishment
  • Figure 15.2 Vaccine CMOs: Distribution by Company Size and Geographical Location
  • Figure 15.3 World Map Representation: Distribution by Geography
  • Figure 15.4 Vaccine CMOs: Distribution by Types of Service(s) Offered
  • Figure 15.5 Vaccine CMOs: Distribution by Additional Services Offered and Location of Headquarters
  • Figure 15.6 Vaccine CMOs: Distribution by Scale of Operation
  • Figure 15.7 Vaccine CMOs: Distribution by Type of Expression System(s) Used
  • Figure 15.8 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
  • Figure 16.1 Concluding Remarks: Overall Market Landscape
  • Figure 16.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 16.3 Concluding Remarks: Academic Grant Analysis
  • Figure 16.4 Concluding Remarks: Partnerships and Collaborations
  • Figure 16.5 Concluding Remarks: Start-up Health Indexing
  • Figure 16.6 Concluding Remarks: Market Forecast and Opportunity Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!